Paper20690807
Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US.
Cronin KA and 4 others. Cancer Invest, 2010. Cited by 151 papers, by iCite.
Cite this record
ConductScience Library. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Papers, record 20690807. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20690807
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Population Surveillance | Major topic |
| Erb-b2 Receptor Tyrosine Kinases | Major topic |
| SEER Program | Major topic |
| Black or African American | |
| Asian | |
| Female | |
| Hispanic or Latino | |
| Humans | |
| Middle Aged | |
| Multivariate Analysis | |
| Neoplasm Staging | |
| Prevalence | |
| United States | |
| White People |
Source PubMed
Grants22
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| N01-PC-35145 | NCI NIH HHS | United States | PubMed | PubMed | |
| N01 PC035133 | NCI NIH HHS | United States | N01PC035133 | PubMed | NIH RePORTER |
| N01-PC-35139 | NCI NIH HHS | United States | PubMed | PubMed | |
| N01-PC-35135 | NCI NIH HHS | United States | PubMed | PubMed | |
| N01-PC-35133 | NCI NIH HHS | United States | PubMed | PubMed | |
| N01 PC035139 | NCI NIH HHS | United States | N01PC035139 | PubMed | NIH RePORTER |
| N01 PC035137 | NCI NIH HHS | United States | N01PC035137 | PubMed | NIH RePORTER |
| N01 PC035142 | NCI NIH HHS | United States | N01PC035142 | PubMed | NIH RePORTER |
| Z99 CA999999 | Intramural NIH HHS | United States | Z99CA999999 | PubMed | NIH RePORTER |
| N01 PC035141 | NCI NIH HHS | United States | N01PC035141 | PubMed | NIH RePORTER |
| N01 PC035138 | NCI NIH HHS | United States | N01PC035138 | PubMed | NIH RePORTER |
| N01 PC035145 | NCI NIH HHS | United States | N01PC035145 | PubMed | NIH RePORTER |
| N01-PC-35138 | NCI NIH HHS | United States | PubMed | PubMed | |
| N01-PC-35142 | NCI NIH HHS | United States | PubMed | PubMed | |
| N01-PC-35137 | NCI NIH HHS | United States | PubMed | PubMed | |
| N01 PC035143 | NCI NIH HHS | United States | N01PC035143 | PubMed | NIH RePORTER |
| N01 PC035136 | NCI NIH HHS | United States | N01PC035136 | PubMed | NIH RePORTER |
| N01-PC-35141 | NCI NIH HHS | United States | PubMed | PubMed | |
| N01-PC-35143 | NCI NIH HHS | United States | PubMed | PubMed | |
| N01-PC-35136 | NCI NIH HHS | United States | PubMed | PubMed |
References15
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16809727 | HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. | J Clin Oncol | 2006 | https://conductscience.org/library/papers/16809727 | PubMed |
| 2 | 16085689 | Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer. | Ann Oncol | 2005 | https://conductscience.org/library/papers/16085689 | PubMed |
| 3 | 18256926 | Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program. | Breast Cancer Res Treat | 2009 | https://conductscience.org/library/papers/18256926 | PubMed |
| 4 | 3798106 | Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. | Science | 1987 | https://conductscience.org/library/papers/3798106 | PubMed |
| 5 | 1351538 | Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. | J Clin Oncol | 1992 | https://conductscience.org/library/papers/1351538 | PubMed |
| 6 | 16208704 | Race modifies the association between breast carcinoma pathologic prognostic indicators and the positive status for HER-2/neu. | Cancer | 2005 | https://conductscience.org/library/papers/16208704 | PubMed |
| 7 | 2470152 | Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. | Science | 1989 | https://conductscience.org/library/papers/2470152 | PubMed |
| 8 | 1973070 | HER-2/neu amplification predicts poor survival in node-positive breast cancer. | Cancer Res | 1990 | https://conductscience.org/library/papers/1973070 | PubMed |
| 9 | 15868434 | Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. | Breast Cancer Res Treat | 2005 | https://conductscience.org/library/papers/15868434 | PubMed |
| 10 | 12048273 | Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. | J Natl Cancer Inst | 2002 | https://conductscience.org/library/papers/12048273 | PubMed |
| 11 | 15917412 | Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. | J Clin Pathol | 2005 | https://conductscience.org/library/papers/15917412 | PubMed |
| 12 | 12529347 | Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. | J Natl Cancer Inst | 2003 | https://conductscience.org/library/papers/12529347 | PubMed |
| 13 | 16236737 | Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. | N Engl J Med | 2005 | https://conductscience.org/library/papers/16236737 | PubMed |
| 14 | 16236738 | Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. | N Engl J Med | 2005 | https://conductscience.org/library/papers/16236738 | PubMed |
| 15 | 16757721 | Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. | JAMA | 2006 | https://conductscience.org/library/papers/16757721 | PubMed |
Cited by112
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 151 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42955226 | Economic evaluation of pertuzumab in early versus late settings of HER2-positive breast cancer: a systematic review. | Eur J Health Econ | 2026 | https://conductscience.org/library/papers/42955226 | PubMed |
| 42615383 | Membrane-Bound Multimodal Plasmonic Transducers for Noninvasive, In Situ Monitoring and Control of CAR T Cells Against Heterogeneous Solid Tumors. | Adv Mater | 2026 | https://conductscience.org/library/papers/42615383 | PubMed |
| 42123574 | MicroRNA-Directed Biomarkers and Breast Cancer Therapeutics-Potential to Advance Personalised Approaches in Clinical Trials. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42123574 | PubMed |
| 42089011 | Pulmonary Hypertension Following the Use of Trastuzumab Biosimilars. | Case Rep Pulmonol | 2026 | https://conductscience.org/library/papers/42089011 | PubMed |
| 42018554 | Human Epidermal Growth Factor Receptor 2 Expression in Prostatic Carcinomas: A Systematic Review and Meta-Analysis of a Potential Therapeutic Target. | Prostate | 2026 | https://conductscience.org/library/papers/42018554 | PubMed |
| 41979751 | Mean platelet volume-to-albumin ratio as a predictor of pathological complete response in HER2-positive breast cancer undergoing neoadjuvant chemotherapy. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41979751 | PubMed |
| 41971926 | Fam-trastuzumab deruxtecan in a patient with metastatic human epidermal growth factor receptor 2-positive breast cancer and pre-existing cardiac failure: a case report. | AME Case Rep | 2026 | https://conductscience.org/library/papers/41971926 | PubMed |
| 41612284 | Cost-utility and budget impact analysis of biosimilar trastuzumab for early-stage HER2-positive breast cancer in Thailand: an updated evaluation supporting expanded access. | BMC Health Serv Res | 2026 | https://conductscience.org/library/papers/41612284 | PubMed |
| 41296586 | Challenges & recommendations for identification of human epidermal growth factor receptor -2 (HER2)-low metastatic breast cancer in India: Expert opinion statement. | Indian J Med Res | 2025 | https://conductscience.org/library/papers/41296586 | PubMed |
| 40828885 | HER2 alterations across solid tumors: implications for comprehensive testing. | Oncologist | 2025 | https://conductscience.org/library/papers/40828885 | PubMed |
| 40826168 | Novel anti-HER2 nanobody-drug conjugates with enhanced penetration of solid tumor and BBB, reduced systemic exposure and superior antitumor efficacy. | Acta Pharmacol Sin | 2026 | https://conductscience.org/library/papers/40826168 | PubMed |
| 40715921 | FKBP10 expression and TP53 mutation predict prognosis and chemotherapy response in triple-negative breast cancer. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40715921 | PubMed |
| 40623091 | Advancing treatment in HER2-positive metastatic breast cancer: the role of tucatinib. | Future Oncol | 2025 | https://conductscience.org/library/papers/40623091 | PubMed |
| 40507330 | Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Early Breast Cancer Treatment and Outcomes by Risk of Recurrence: A Retrospective US Electronic Health Records Study. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40507330 | PubMed |
| 40490846 | Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trial. | Int J Cancer | 2025 | https://conductscience.org/library/papers/40490846 | PubMed |
| 40470054 | Machine learning-based fusion model for predicting HER2 expression in breast cancer by Sonazoid-enhanced ultrasound: a multicenter study. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/40470054 | PubMed |
| 40406477 | Evaluation of pathological complete response rates in breast cancer patients undergoing neoadjuvant therapy. | Rev Bras Ginecol Obstet | 2025 | https://conductscience.org/library/papers/40406477 | PubMed |
| 40405946 | T-DM1: a promising adjuvant therapy option for stage I HER2-positive breast cancer-interpreting ATEMPT trial results from a clinical perspective. | Gland Surg | 2025 | https://conductscience.org/library/papers/40405946 | PubMed |
| 40192324 | Treatment patterns and associated outcomes among patients with HER2+ metastatic breast cancer in the United States: an observational cohort study. | Oncologist | 2025 | https://conductscience.org/library/papers/40192324 | PubMed |
| 40085414 | Postoperative radiotherapy improves long-term survival in HER2-positive metastatic breast cancer: real-world evidence from the latest SEER database. | Breast Cancer Res Treat | 2025 | https://conductscience.org/library/papers/40085414 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| EREG | 2069 | PubTator's text mining | https://conductscience.org/library/genes/2069 | NCBI Gene |
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| NR4A1 | 3164 | PubTator's text mining | https://conductscience.org/library/genes/3164 | NCBI Gene |
| PGR | 5241 | PubTator's text mining | https://conductscience.org/library/genes/5241 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20690807
GET https://conductscience.org/api/papers/v1/20690807/grants?page=2